Kalorama Information (New York) reported that the worldwide market for human-derived blood products, testing, and typing products, and plasma and blood collection equipment exceeded $20 billion at the end of 2005.
Kalorama said the total global value of blood products alone is just shy of $14 billion in 2005, with the lion’s share attributable to red blood cells (RBCs) at more than $7 billion.
Demand for immunoglobulins or antibodies stood at nearly $3 billion in 2005 and is rising by 6%-8% per year, making it the driving force behind plasma collection. Other human plasma-derived products, such as platelets, clotting factors, and alph-1 proteinase inhibitors, also played a significant role in strong revenues, valued at $2.5 billion, Kalorama said.
At the same time the blood products market escalates, so too are the markets for blood testing and typing products, blood collection equipment, and synthetic blood products. Nucleic acid tests, for example, currently at $953 million, are expected to increase by 11.5% to over $2 billion by 2012. Similarly, the market for recombinant factors, which currently stands at over $4 billion, is expected to rise to more than $7 billion by 2012.
“Global demand for blood products, particularly in developed countries where the technology is readily available and rapidly advancing will continue to rise at a healthy rate as the world population ages and requires increasingly intricate operations and testing,” said Alison Sahoo, the report’s author. “As they reach the market by 2007, we also anticipate the emergence of hemoglobin-based oxygen carriers and PFC-based products to play a significant role in market growth.”
Kalorama Information, a division of MarketResearch.com, supplies independent market research for the life sciences.
StatSure to restate earnings
StatSure Diagnostic Systems (Framingham, Massachusetts) reported that on Oct. 12, the audit committee of its board concluded, based upon the recommendation of the company’s management and independent auditors, that the company will restate its previously issued financial statements for the quarters ended March 31, 2005, June 30, 2005, and Sept. 30, 2005, and for the year ended Dec. 31, 2005, included in the company’s annual report on Form 10-KSB, and for the quarters ended March 31 and June 30.
The company’s previously issued financial statements for these periods should therefore no longer be relied upon, it said.
In the course of a routine SEC review of the prior Company periodic filings, the SEC issued a comment letter dated Oct. 4, 2006, alerting the company to a possible incorrect application of certain accounting principles.
The need to restate the company’s financial statements arises from incorrect application of generally accepted accounting principles related to the beneficial conversion feature on the issuance of the convertible debt by the company, and revised calculations of the Employee Stock Options pursuant to FIN 28:
StatSure Diagnostic Systems is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases. In addition, the company has developed and is marketing a product line of patented, oral-fluid collection devices.
Del Global relocates HQ
Del Global Technologies (Valhalla, New York) reported that it has relocated its corporate offices from Valhalla, New York, to Franklin Park, Illinois, in suburban Chicago. The new address is 11550 West King Street, Franklin Park, IL 60131. The company said that the relocation will consolidate Del Global’s corporate office into the headquarters of the company’s Del Medical Systems Group, which markets and sells medical imaging and diagnostic systems worldwide.
Del Global manufactures diagnostic imaging systems for medical, dental and veterinary applications through the Del Medical Systems Group.